Bristol Myers Squibb's anemia drug Reblozyl missed the primary endpoint in the Phase III INDEPENDENCE trial for myelofibrosis-associated anemia, failing to achieve sustained transfusion independence for 12 weeks within the initial 24 weeks of treatment. Despite statistically missing the outcome, BMS reported a numerical improvement in transfusion independence and favorable secondary outcomes including hemoglobin increases. The company plans to engage regulators for possible submissions, citing the unmet treatment need, while analysts cited a lack of quantitative data as a limitation for assessment.